The CSL share price is down 14% from its 52-week high. Is it a buy?

Let's see if analysts think that investors should be snapping up this quality company's shares.

| More on:
A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is edging lower on Thursday.

In morning trade, the biotechnology giant's shares are down slightly to $269.76.

This means that its shares are now down 14% from its 52-week high and within touching distance of a 52-week low.

Does this make it a buy? Let's see what analysts are saying about the company.

Is the CSL share price undervalued?

While there are concerns over what impact Donald Trump could have on the healthcare sector in the United States, a large number of brokers believe the risk/reward on offer with CSL's shares is very favourable.

One of those brokers is Goldman Sachs, which has just initiated coverage on the CSL Behring owner with a buy rating and $325.40 price target. Based on the current CSL share price of $269.76, this implies potential upside of 20% for investors over the next 12 months.

What is it saying about CSL?

Goldman acknowledges that the last five years have been challenging for the company. So much so, this normally reliable investment is down 17% over the period.

However, the broker believes that the worst is now behind the company and that the next few years will look very different. It said:

The last five years have been particularly challenging for CSL, with the business navigating material inflationary pressures to its plasma collections costs, the threat of a new entrant (anti-FcRn) in its core Immunoglobulin (IG) market, its Vifor acquisition encountering the entry of generics quicker than anticipated and late-stage R&D setbacks.

Whilst some of these developments have led to structural changes to CSL's business, we believe the company's proactive investments in its IG franchise and new product launches in the Behring portfolio are set to increase ROIC in this new operating environment.

The broker is forecasting double digit IG growth through to FY 2028, a strong gross margin recovery, and a rebound in Seqirus growth from depressed US influenza vaccination rates.

Looking cheap

In light of the above, Goldman Sachs believes that CSL's shares are cheap at current levels and deserve a re-rating. It explains:

Our 25.6x Forward 12 months EV/EBIT multiple for CSL is based on the stock's history relative to the index (ASX200) and relative to its peers, normalising for differences in growth. Over the last 10 years, CSL's premium to the ASX 200 has ranged from 1.5x-3.0x.

We adopt a premium of 1.8x as part of our valuation which is close to the 10-year average noting the current share price values the business cheaper relative to its 5 and 10-year averages. We believe ongoing momentum in CSL's IG revenue growth, Gross Margin recovery and execution on market share initiatives in Hemophilia and HAE are key drivers in driving re-rating.

Elsewhere, Ord Minnett put a buy rating and $318.00 price target on its shares this week, Citi put a buy rating and $345.00 price target on them last week, and UBS put a buy rating and $330.00 price target on them last month. All these price targets offer upside of approximately 18%+ for the CSL share price.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »